Latest Conference Articles

Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.

A study out of Boston observes little to no difference in previous biologic prescription and worsened odds of infection nor death during the pandemic.

An assessment of real-world registry data suggest the biologic provides significant benefit outside of clinical trials.

A comparison of pooled phase 3 data showed patients treated with the IL-17A inhibitor fared better than those on ustekinumab, without influence from their PsA status.

A network meta-analysis shows favorability with dupilumab and abrocitinib in efficacy and safety outcomes among adults and adolescents.

The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.

The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab.

All patients treated with 2.5 benzoyl peroxide and a stabilized cosmetic retinol saw significant improvement in lesion count reduction after 12 weeks.

Implementing alternative therapies does not mean abandoning conventional medications, stresses Peter Lio, MD. There must be a balance that works for the patient's situation.

Seemal Desai, MD, gives an overview of the most promising research and therapies for patient of color populations.

Lawrence Eichenfield, MD, discusses future prescribing plans and safety assessment for the topical JAK 1/2 inhbitor.

New cross-sectional survey data suggest quality-of-life and psychological outcomes may differ in the most common chronic skin disease patient populations.

The investigative topical cream benefits adolescent and adult skin clearance and itch. A study author discusses keeping it available to patients if it reaches the market.

A post-hoc analysis shows that the human monoclonal antibody was linked to sustained improvements according to different disease measurements through week 52.

Patients who received ixekizumab achieved PASI 90 at a median of 43.0 days and PASI 100 at 85.0 days.

In a Q&A, Peter Lio, MD, discusses some evidence for using integrative therapies with patients.

A pair of AAD VMX studies show long-term repigmentization is possible with the JAK inhibitor. An expert explains why the drug could make history.

The oral S1P receptor modulator has promise to break new ground for disease modification.

Brett King, MD, PhD, discusses new ground that that oral JAK inhibitor breaks in the alopecia areata therapeutic field.

The investigative JAK inhibitor therapy provided significantly better skin clearance and resolved pain at 8 weeks with 2 different doses.

Esther Freeman, MD, PhD, talks about the various levels of dermatologic severity associated with COVID-19.

Rebecca Kazin, MD, offers some insight into her cosmetic dermatology practices, including a new hair product that she developed.

Phase 3 open-label extension data suggest young patients may even improve skin clearance scores after a year on the biologic therapy.

A comparison of the IL-17 inhibitors suggest the more dynamic pathway-targeting biologic is more efficacious, but linked to more oral candidiasis.

A single-injection co-formulation of pramlitide and insulin may be a better alternative to separate administrations of both key treatments in adults with T1D, particularly following meals.

A majority of surveyed patients and providers want to continue telemedicine follow-up visits after the pandemic ends.

Stimulating steroid receptor co-activators may play a role in repairing heart tissue following severe myocardial infarction.

In ENDO 2021 data, approximately one-third of an observed COVID-19 patient population in Italy was still experiencing signs of thyroid inflammation after 3 months,

Many patients with genetic obesity disorder experience resistance to treatment, including intensive lifestyle therapy.

Evening and late-night preferences of women with GDM is linked to a significantly greater risk of preeclampsia and NICU treatment.